Zenas BioPharma, Inc.

NASDAQ:ZBIO

Biotechnology

Healthcare
$26.42 +3.46%

+$0.64 today

Market cap
$1.79B
Beta
-0.69
P/E (TTM)
-2.5
EPS (TTM)
-$7.64
52W Low $8.91High $44.60

Volume 0.48M

Average 0.71M

ZBIO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Zenas BioPharma, Inc.NASDAQ: ZBIO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $60.44M rose 73.1% year over year, behind the +137.9% change in trailing-twelve-month research & development. Sequentially, it fell 72.8% from the prior quarter. Over 3 fiscal years it compounded at +38.9% a year.

Context

  • Research & development amounted to 1680.6% of revenue in FY2025, down 1102.1 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +73.1% toward the trailing-twelve-month pace of +137.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$60.44M-72.8% QoQ
Last fiscal yearDec 2025
$168.06M+20.8% YoY
LTMMar 2026
$360.26M+137.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+73.1%——
1 year+20.8%——
3-year CAGR+38.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
168.06M USD
Year-over-year change
+20.8%
3-year CAGR
+38.9%

Research & Development vs competitors

How ZBIO compares with its peers on the latest reported figures

  • ZBIO's LTM Mar 2026 research & development of $360.26M is the 2nd highest of the 8 companies compared; the peer median is $139.61M.
  • Its year-over-year change of +137.9% is the highest of 8, against a peer median of +17.5%.
  • Over three fiscal years its annual growth of +38.9% compares with a peer median of +2.9%.
ZBIO Competitors Peer median
Research & Development for ZBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMVTImmunovant, Inc.LTM Sep 2026$468.85M +16.2%+41.8%6608.2%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$360.26M +137.9%+38.9%—
ANNXAnnexon, Inc.LTM Mar 2026$172.31M +17.5%+18.0%—
UPBUpstream Bio, Inc.LTM Mar 2026$147.57M +91.5%+94.3%4442.3%
TRAXFirst Tracks Biotherapeutics IncFY2025$139.61M -8.4%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M +60.6%-12.2%677.9%
QTTBQ32 Bio Inc.LTM Mar 2026$15.25M -66.4%-18.8%28.4%
TLSATiziana Life Sciences LtdFY2025$10.28M +96.6%-13.6%—
Peer median (excluding ZBIO) $139.61M+17.5%+2.9%2560.1%

Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue050M5M10M
Cost of Revenue61.69M0139.14M0
Gross Profit(61.69M)50M(134.14M)10M
Gross Margin—100.0%-2682.8%100.0%
Research & Development62.69M60.03M139.14M168.06M
Selling, General & Admin13.51M17.11M29.75M53.32M
Operating Expenses14.51M87.15M29.75M221.39M
Depreciation & Amortization78K113K137K56K
EBITDA(75.12M)(27.03M)(156.42M)(370.43M)
EBITDA Margin—-54.1%-3128.4%-3704.3%
Operating Income(76.2M)(37.15M)(163.89M)(211.39M)
Operating Margin—-74.3%-3277.8%-2113.8%
Interest Income00012.15M
Interest Expense0007.33M
Other Income / Expenses(43.08M)324K7.33M(166.43M)
Income Before Tax(119.28M)(36.82M)(156.56M)(377.82M)
Pre-Tax Margin—-73.6%-3131.2%-3778.2%
Income Tax Expense0301K429K(79K)
Net Income(119.28M)(37.12M)(156.99M)(377.74M)
Net Margin—-74.2%-3139.8%-3777.4%
EPS (Basic)(3.11)(0.97)(3.76)(8.44)
EPS (Diluted)(3.11)(0.97)(3.76)(8.44)
Weighted Avg Shares38.32M38.32M41.79M44.73M
Weighted Avg Shares (Diluted)38.32M38.32M41.79M44.73M

Zenas BioPharma, Inc.

NASDAQ:ZBIO

Intrinsic Alpha fair value

Locked

Current Price

$26.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.